期刊
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
卷 128, 期 -, 页码 8-17出版社
ELSEVIER
DOI: 10.1016/j.ejps.2018.11.023
关键词
Cancer; RGD; Integrin; Polymer; Liposome
资金
- National Natural Science Foundation of China [21776046, 21606043]
- Fundamental Research Funds for the Central Universities [2242017R30002]
- Recruitment Program for Young Professionals (the Thousand Youth Talents Plan)
Over the past few decades, as the demand for cancer treatment has increased, more rational treatment options (considering size, mode of administration, biocompatibility, efficacy, etc.) and plenty of specifically active targeted nanovehicles have been developed. Integrin receptors targeting are one of the most frequently used approaches because of its highly expressed in cancer cells. In particular, the arginine-glycine-aspartic acid (RGD) peptide and its derivatives have been widely used as ligands for integrin to increase direct targeting capabilies. Polymers as well as liposomes are commonly used as nanovehicles for drug delivery. A variety of work is focused on the RGD-modified polymer and liposome nanovehicles for cancer therapeutics. The goal of this article is to review the published literature in recent years concerning the RGD-modified liposome and polymer nanovehicles to highlight its successful designs for improving cancer therapy and discuss the current challenges as well as the possible development prospects.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据